These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-000195-13 A Phase II, Randomized, Open label, Controlled, Multicenter Study to Evaluate the Safety, Immunogenicity and Induction of Immunological Memory after Two or Three Doses of Novartis Meningococcal ACWY C... 2006-10-02 due-trials
Completed, but no date, and reported results 2005-000924-18 A Phase III, Multi-Center, Open-Label, Controlled, Randomized Study to Evaluate the Immunogenicity, Safety, Tolerability and the Ability to Prime for Memory of Chiron Meningococcal C Conjugate Vaccine... bad-data
Reported results 2006-001522-84 A Phase 2, Open Label, Multi-Center, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine +/- OMV, when Administered to Healthy I... 2008-08-15 due-trials
Reported results 2006-001676-21 A phase IV, open-label, single-center study in adolescents and adults: Evaluation of immunogenicity and safety of the first booster immunization with Chiron’s TBE vaccine for adults in participants of... 2011-10-07 due-trials
Reported results 2006-002649-35 A Phase IV, Single-Centre, Observer-Blind, Controlled, Randomized Study to Compare the Safety and Immunogenicity of Fluvirin® to Influvac® Administered to Healthy Children 3 to 12 Years of Age. 2006-11-22 due-trials
Completed, but no date, and reported results 2006-003181-34 A Phase II, Observer-Blind, Randomized, Parallel Groups, Single Center, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of One and Two 0.25 mL Intramuscular Doses of FLUAD™ versus... bad-data
Reported results 2006-003476-35 A Phase II, Single Centre, Open-label, Randomized Study to Investigate Meningococcal Serogroup A, C, W-135 and Y Saccharide Specific B Cell Response to a Primary and a Booster Course of the Novartis M... 2009-06-19 due-trials
Reported results 2006-005203-33 A Phase II, Multicenter, Exploratory Study to Evaluate Safety and Immunogenicity of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adults Unprimed and Primed with MF59-adjuvanted or Non-adjuvanted H5N3 ... 2008-01-19 due-trials
Reported results 2006-005428-18 A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subject... 2007-10-03 due-trials
Completed, but no date, and reported results 2006-005558-63 A phase III, randomized, controlled, observer-blind, single-center study to compare immunogenicity and safety of an MF59-adjuvanted inactivated subunit influenza vaccine (FLUAD™) to those of a nonadju... bad-data
Reported results 2006-005589-38 A Phase 2, Single Blind, Single Center, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine +/- OMV, when Administered to Healthy Infants 6-... 2008-06-05 due-trials
Completed, but no date, and reported results 2007-000165-38 A Phase II, Open-label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Booster Dose of FLUAD-H5N1 (Surface Antigen Adjuvanted with MF59C.1) Influenza Vaccine in Non-elderly Adult and E... bad-data
Reported results 2007-000963-28 A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2007-2008, when Administered ... 2007-07-17 due-trials
Completed, but no date, and reported results 2007-000964-26 A Phase II, Open Label, Uncontrolled, Multi-Center Study to support annual strain update and to Evaluate Safety and Immunogenicity of FLUAD Surface Antigen, Inactivated, (Adjuvanted with MF59C.1) Infl... bad-data
Completed, but no date, and reported results 2007-000966-19 A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD Surface Antigen, Inactivated, (Adjuvanted with MF59C.1) Influenza Vaccine, Formulation 2007-2008... bad-data
Reported results 2007-001403-38 A Phase III, multicenter, uncontrolled, open-label study to evaluate safety and immunogenicity of Begrivac®, preservative free, inactivated split influenza vaccine, using the strain composition 2007/2... 2007-07-10 due-trials
Reported results 2007-001404-20 A Phase III, multicenter, uncontrolled, open-label study to evaluate safety and immunogenicity of a single intramuscular dose of a trivalent subunit influenza vaccine produced in mammalian cell cultur... 2007-08-01 due-trials
Reported results 2007-001534-13 A Combined Phase II/III, Observer-Blind, Randomized, Multi-center Study to Evaluate Safety, Tolerability and Immunogenicity of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cell C... 2008-07-24 due-trials
Reported results 2007-001563-29 A Phase 2, Multi-Center, Open-label Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2, 6-Month Schedule and of a Single d... 2009-11-09 due-trials
Reported results 2007-002063-27 A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of FLUVIRIN® Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2007-2008, when Admini... 2007-08-16 due-trials
Reported results 2007-002480-27 A Phase II, Randomized, Controlled, Observer-blind, Single-center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Subjects aged 6 months t... 2009-05-18 due-trials
Completed, but no date, and reported results 2007-002712-25 A Phase II, Randomized, Placebo-controlled, Observer-blind, Multi Center Study on the Safety and Immunogenicity of Novartis Tetravalent Influenza Vaccine (containing both interpandemic strains and H5N... bad-data
Completed, but no date, and reported results 2007-002871-15 A Phase III, Randomized, Observer-Blind, Placebo-Controlled, Multicenter Study to Assess Clinical Efficacy of a Cell-Derived Subunit Influenza Vaccine and an Egg-Derived Subunit Influenza Vaccine in t... bad-data
Reported results 2007-002872-32 A Phase IV, Multi-Center, Active-Controlled, Observer-Blind Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced either in Mammalian Cell Culture (Optaflu®) or in Embryonated... 2008-07-03 due-trials
Reported results 2007-003339-22 A Phase II, Observer-Blind, Parallel Groups, Single-Center, Extension Study to Evaluate the Immunogenicity and Safety Following a Single Intramuscular Dose of FLUAD or Vaxigrip Influenza Vaccines in H... 2008-06-11 due-trials
Exempt, with results 2007-003511-31 Phase I/II, Randomized, Observer-blind, Placebo-controlled, Single-Center Study of the Tolerability, Immunogenicity and Efficacy (following Helicobacter pylori infectious challenge) of Novartis’ Inves... 2010-03-08 not-yet-due
Reported results 2007-003786-41 A Phase III, randomized, observer-blind, controlled, multi-center clinical study to evaluate the efficacy, safety and immunogenicity of one and two intramuscular doses of FLUAD versus control vaccines... 2010-08-05 due-trials
Reported results 2007-004754-82 A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity after One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine Administered to Healthy Infants ... 2010-10-22 due-trials
Reported results 2007-004978-16 A Phase 2, Open-label, Controlled, Multi-center Study to Evaluate Meningococcal ACWY Antibody Response in Children Aged 40 and 60 Months who Have Previously Received Novartis MenACWY Conjugate Vaccine... 2010-09-20 due-trials
Reported results 2007-007781-38 A Phase 3, Partially Blinded, Randomized, Multi-Center, Controlled Study to Evaluate Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered... 2010-01-22 due-trials
Reported results 2008-000887-18 A Phase III, multicenter, uncontrolled, open-label study to evaluate safety and immunogenicity of Begrivac®, preservative free, inactivated split influenza vaccine, using the strain composition 2008/2... 2008-07-21 due-trials
Reported results 2008-000895-25 A Phase II, Open-label, multi center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects 2009-11-05 due-trials
Reported results 2008-000939-17 A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of FLUVIRIN® [Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur], Formulation 2008-2009, when Admi... 2008-08-07 due-trials
Completed, but no date, and reported results 2008-001047-19 A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUad Surface Antigen, Inactivated, Adjuvanted with MF59C.1 Influenza Vaccine, Formulation 2008-2009, ... bad-data
Completed, but no date, and reported results 2008-001079-31 A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2008-2009, when Administered ... bad-data
Reported results 2008-001592-30 A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered with or... 2010-07-21 due-trials
Exempt, with results 2008-002602-20 A Phase Ib, Randomized, Observer-Blind, Multicenter, Factorial-Design Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Injections of Trivalent Inactivated Influenza Vaccine with or... 2009-03-30 not-yet-due
Reported results 2008-003008-72 A Phase III, Randomized, Open-label, Single-center Study to Evaluate the Safety and Immunogenicity of a FLUAD-H5N1 Influenza Vaccine in Adult Subjects Using Four Different Vaccination Schedules 2009-06-12 due-trials
Reported results 2008-003871-32 A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of a Monovalent A/H5N1 Influenza Vaccine Adjuvanted with MF5... 2009-11-23 due-trials
Reported results 2008-006301-17 A Phase 3, Open label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster at 12 Months... 2010-08-16 due-trials
Reported results 2009-010106-11 A Phase 2 Observer-Blind Randomized Controlled Multicenter Dose-Ranging and Formulation-Finding Study of a new Novartis Meningococcal B Recombinant Vaccine evaluating the immunogenicity, tolerability ... 2011-12-12 due-trials
Completed, but no date, and reported results 2009-010145-31 A phase IV, open-label, multi-center follow-up study to determine the persistence of tick-borne encephalitis (TBE)-specific antibody responses among children and adolescents previously immunized again... bad-data
Reported results 2009-010565-23 A Phase III, multicenter, uncontrolled, open-label study to evaluate safety and immunogenicity of Begrivac®, preservative free, inactivated split influenza vaccine, using the strain composition 2009/2... 2009-06-24 due-trials
Completed, but no date, and reported results 2009-010586-23 A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD Surface Antigen, Inactivated, Adjuvanted with MF59C.1 Influenza Vaccine, Formulation 2009-2010, ... bad-data
Completed, but no date, and reported results 2009-010598-19 A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2009-2010, when Administered ... bad-data
Reported results 2009-011004-33 A Phase II, single center, uncontrolled, open label study to evaluate safety and immunogenicity of FLUVIRIN® [Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur], Formulation 2009/2010, when Admi... 2009-07-30 due-trials
Reported results 2009-011676-30 A Phase 2b, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis Meningococcal B Recombinant Vaccine Administered at 12, 18 ... 2012-01-09 due-trials
Reported results 2009-012385-31 A Phase II, Randomized, Controlled, Double-blind, Multi-center, Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 (Surface Antigen Adjuva... 2009-12-17 due-trials
Reported results 2009-013054-33 A Phase 2, Open-Label, Single-Center, Extension Study Evaluating Antibody Persistence compared to Naïve Children and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ V... 2012-05-22 due-trials
Reported results 2009-013075-21 A Phase 2, Open-Label, Single-Center, Extension Study Evaluating Antibody Persistence compared to Naïve Children and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ ... 2012-05-23 due-trials
Reported results 2009-013639-39 A Randomized, Single-blind, Dose-Ranging, Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Cell-Derived, Inactivated Novel Swine Ori... 2011-03-11 due-trials
Reported results 2009-013640-37 A Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Cell-derived, Inactivated Novel Swine Orig... 2011-08-10 due-trials
Reported results 2009-013671-21 A Randomized, Single-blind, Dose-Ranging, Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Egg-Derived, Inactivated Novel Swine Orig... 2011-04-01 due-trials
Reported results 2009-013672-45 A Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and non-Adjuvanted Egg-derived, Inactivated Novel Swine Or... 2011-07-01 due-trials
Completed, but no date, and reported results 2009-013904-30 A Phase II, Open Label Study to Evaluate the Immunogenicity, Tolerability and Safety of a MF59-Adjuvanted, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy... bad-data
Reported results 2009-018101-52 Title of the trial: A Phase 3, Open-Label, Multi-Center, Extension Study of V72P13E1 to Assess Antibody Persistence at One Year After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococca... 2011-09-20 due-trials
Reported results 2010-018371-18 A Phase III, multicenter, uncontrolled, open-label study to evaluate safety and immunogenicity of Begrivac®, preservative free, inactivated split influenza vaccine, using the strain composition 2010/2... 2010-07-08 due-trials
Completed, but no date, and reported results 2010-018583-17 A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2010-2011, when Administered ... bad-data
Completed, but no date, and reported results 2010-018603-29 A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD Surface Antigen, Inactivated, Adjuvanted with MF59C.1 Influenza Vaccine, Formulation 2010-2011, ... bad-data
Reported results 2010-019040-39 A Phase III, multicenter, uncontrolled, open label study to evaluate safety and immunogenicity of FLUVIRIN® [Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur], Formulation 2010/2011, when admin... 2010-07-27 due-trials
Trial is partly outside EEC, and reported results 2010-020840-36 A Phase II Randomized, Observer-Blind, Multi-Center, Controlled Study of a Trivalent Group B strep. Vaccine in Healthy Pregnant Women. 2013-10-17 bad-data
Reported results 2010-021528-81 A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According ... 2015-07-01 due-trials
Reported results 2010-021644-18 A Phase IIIB, observer-blind, randomized, parallel groups, extension study to evaluate the immunogenicity and safety following a single intramuscular dose of FLUAD or Agrippal S1 influenza vaccines in... 2011-12-22 due-trials
Completed, but no date, and reported results 2010-021841-38 A Phase II Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface, Antigen, Inactivated, Adjuvanted with MF59C.1 Influenza Vaccine (Fluad), Formulation 2011/20... bad-data
Completed, but no date, and reported results 2010-021874-12 A Phase 2, Randomized, Observer–blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of Three Formulations of the NVGH Glycoconjugate Vaccine against S. Typhi in Adult Subj... bad-data
Reported results 2010-023523-23 Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB with OMV + MenACWY Combination Vaccina... 2012-09-12 due-trials
Reported results 2010-023791-63 A Phase II, Randomized, Controlled, Observer-Blind, Clinical Study to Evaluate the Humoral and Cell Mediated Immunity and Safety of Two Intramuscular Doses of Fluad® or Agrippal® in Previously Unvacci... 2012-02-14 due-trials
Completed, but no date, and reported results 2010-023858-37 A Phase IIIb, Open-Label, Controlled, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C ... bad-data
Completed, but no date, and reported results 2010-024400-98 A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2011-2012, when Administered ... bad-data
Completed, but no date, and reported results 2010-024613-31 A Phase III Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture (Optaflu®), Form... bad-data
Reported results 2011-000395-34 A Phase 2, randomized, comparative, multicenter study evaluating the safety and immunogenicity of a new liquid formulation of adsorbed meningococcal C vaccine (conjugate CRM-197), a lyophilized mening... 2012-11-02 due-trials
Reported results 2011-000475-14 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines when Administered Concomitantly with Novartis Meningococcal ACWY Conjugate Vaccine in Healt... 2012-04-24 due-trials
Reported results 2011-000476-34 A Phase IV,PlaceboControlled,Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix) and Quadrivalent ... 2012-12-20 due-trials
Completed, but no date, and reported results 2011-001333-17 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine when Administered Concomitantly with Novartis Meningococcal ACWY Conjugate Vaccine ... bad-data
Reported results 2011-001448-31 A Phase 2, open-label, single-center, extension study to evaluate the booster response induced by Vi-CRM197 after priming with either Vi-CRM197 or Typherix administered in adult subjects in H01_04TP s... 2011-12-13 due-trials
Reported results 2011-003573-28 A Phase III Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1 when Administered to Adult and Elderly... 2015-05-04 due-trials
Completed, but no date, and reported results 2011-003694-29 A Phase 3b, Multi-Center, Open-label Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy at-risk Adults Studio di Fase 3... bad-data
Reported results 2011-004421-27 A Phase 3b, Randomized, Open-label, Multi-Center Study Assessing Immunogenicity, Safety and 1 Year Persistence of Antibodies after One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine, ad... 2014-05-30 due-trials
Reported results 2011-004931-30 A Phase 3, Open Label, Multi-Center, Extension Study to Assess Antibody Persistence and Response to a Third or Fift Dose of Novartis Meningococcal B Recombinant Vaccine in 4-Year-Old Children Who Pre... 2014-04-09 due-trials
Reported results 2011-005173-23 A Phase III, Multicenter, Observer-blind, Safety and Immunogenicity Study of Rabies Vaccine and Japanese Encephalitis Vaccine Administered Concomitantly and/or Separately According to 1 of 2 Different... 2013-10-28 due-trials
Reported results 2011-006271-18 A Phase 3 Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Influenza Vaccine (Fluvirin®), Flirmulation 2012/2013, when Administered... 2012-08-16 due-trials
Completed, but no date, and reported results 2011-006277-25 A Phase III Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture (Optaflu®), Form... bad-data
Reported results 2012-000063-24 A Ph II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety & Immuno. of AGRIPPAL® S1 Vaccine, Formulation 2012-2013, in Non-elderly Adult and Elderly Subjects 2012-07-30 due-trials
Reported results 2012-000085-38 A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD Surface Antigen, Inactivated, Adjuvanted with MF59C.1 Influenza Vaccine, Formulation 2012-2013, ... 2012-08-14 due-trials
Reported results 2012-000657-30 A Phase IIIB, Open Label, Multi-Center Extension Study of V72_28 to assess antibody persistence, and the safety and tolerability of a booster dose after the completion of the vaccination course in stu... 2016-08-11 due-trials
Trial is outside EEC, and reported results 2012-001223-13 A Phase III, Observer-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced either in Mammalian Cell Culture or in Embryonated Chick... bad-data
Reported results 2012-003740-74 A Multi-Center, Phase IV, Randomized, Controlled, Observer Blind Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Trivalent Subunit Inactivated Influenza Vaccine in Healthy Subjects... 2013-12-16 due-trials
Reported results 2012-005815-25 A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy at-Risk Adults... 2014-04-14 due-trials
Ongoing 2013-000145-39 A Phase 3, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Single Dose of Novartis Meningococcal ACWY Conjugate Vaccine, administered to Healthy T... not-yet-due
Reported results 2013-000545-39 A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine (Agrippal®) in Healthy Adult... 2013-08-20 due-trials
Completed, but no date, and reported results 2013-000601-23 A Phase III, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine (Fluvirin®) in Healthy Adul... bad-data
Reported results 2013-000607-16 A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine Including MF59C.1 Adjuvant (... 2013-08-20 due-trials
Reported results 2013-000621-30 A Phase III, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine Produced in Mammalian Cell ... 2013-09-08 due-trials
Completed, but no date, and reported results 2013-000862-13 A Phase 2, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' M... bad-data
Reported results 2013-002080-26 A Phase III, Observer-Blind, Randomized Multicenter Study to Evaluate the Safety of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cell Culture (tivc) or in Embryonated Eggs (TIV),... 2014-09-15 due-trials
Exempt, with results 2013-002081-39 A Phase I/II, Randomized, Observer-Blind, Multicenter Study to Evaluate Immunogenicity and Safety of Four Influenza Vaccines in Healthy Pediatric Subjects 6 to < 48 Months of Age. 2014-12-08 not-yet-due
Reported results 2013-002454-78 A Phase IIIb, Open Label, Controlled, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of Novartis Meningococcal Group B Vaccine when administered to Immunocompr... 2015-10-22 due-trials
Trial is outside EEC, and reported results 2014-003514-91 A Phase 3, Randomized, Observer-blind, Controlled, Multi-Center Study to Compare the Safety of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine with that of a Licensed Meningococcal ACWY Poly... bad-data
Trial is outside EEC, and reported results 2014-004410-29 A Phase 2b/3, Multi-Center, Observer-Blind, Controlled Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents Aged 11-... bad-data
Trial is outside EEC, and reported results 2014-004446-95 A Phase IV, open-label, controlled, multi-center study to evaluate the 5-year antibody persistence among children who previously received Novartis MenACWY conjugate vaccine at 2 to 10 years of age and... bad-data
Trial is outside EEC, and reported results 2014-004476-30 A Phase 3, Randomized, Comparative, Multicenter Observer-Blind Study Evaluating the Safety and Immunogenicity of Novartis rMenB+OMV NZ Vaccine Formulated with Outer Membrane Vesicle (OMV) Manufactured... bad-data
Trial is outside EEC, and reported results 2014-004492-23 A Phase 3, Single Center, Open-label, Controlled, Randomized Study to Evaluate the Safety and Immunogenicity of Novartis Men ACWY vaccine administered either alone or concomitantly with a Combined Tet... bad-data
Trial is outside EEC, and reported results 2014-004498-17 A Multi-center, Phase III, Randomized, Observer Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Trivalent Subunit Inactivated Influenza Vaccine (Agriflu™) in Healthy Children... bad-data
Trial is outside EEC, and reported results 2014-004515-37 A Phase II, Randomized, Controlled, Open Label, Single-Center Study to Evaluate the Immunogenicity, Safety and Tolerability of Fluad-H5N1 and Seasonal Influenza Vaccine in Adult Subjects. bad-data
Trial is outside EEC, and reported results 2014-004543-12 A Phase II, Observer-Blind, Randomized, Multi-center Study to Evaluate the Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Fluad® and Fluzone® Influenza Vaccines in Healthy Children Aged 6... bad-data
Trial is outside EEC, and reported results 2014-004577-16 A Phase 3b, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of Me... bad-data
Trial is outside EEC, and reported results 2014-004617-82 A Phase 3, Multi-center, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Children, Adolescents and Adults in Russia bad-data
Trial is outside EEC, and reported results 2014-004734-25 A Phase 2, Single-Blind, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine OMV When Administered at an 0-2-6-Month Schedule i... bad-data
Trial is outside EEC, and reported results 2014-004757-14 A Phase III Observer-Blind, Randomized, Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Immunogenicity of Two Trivalent Subunit Inactivated Influenza Vaccines (Agrippal® and Fluvir... bad-data
Trial is outside EEC, and reported results 2014-004973-17 A phase 3, multicenter, open-label study to evaluate immunogenicity and safety of Novartis Meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy subjects from 2 to 18 years in Taiwan. bad-data
Trial is outside EEC, and reported results 2014-004992-21 A Phase 2b/3, Multi-Center, Extension Study of V72P10 to Assess Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10. bad-data
Trial is outside EEC, and reported results 2014-005013-23 A Phase III Open Label, Multi-Center Pediatric Study in China Comparing a Booster Dose of Vaxem™ Hib to HIBERIX® bad-data
Trial is outside EEC, and reported results 2014-005014-36 Phase 2, Observer-Blind, Controlled, Randomized, Multi-Center Extension Study to Evaluate Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenAC... bad-data
Trial is outside EEC, and reported results 2014-005036-33 A phase I study to investigate safety and reactogenicity of Vaxem Hib in healthy children aged 16 – 20 months and infants aged 2 - 4 months. bad-data
Trial is outside EEC, and reported results 2014-005053-40 A Phase III, Observer-Blind, Randomized, Multi-center Study to Evaluate the Safety, Tolerability, and Immunogenicity of Fluad and Agriflu Compared to the Non Adjuvanted Trivalent Influenza Vaccine Flu... bad-data
Trial is outside EEC, and reported results 2014-005055-11 A phase 3, multi-center, observer-blind, placebocontrolled, randomized study to evaluate the immunogenicity and safety of Novartis Meningococcal ACWY conjugate vaccine in healthy subjects from 11 to 5... bad-data
Trial is outside EEC, and reported results 2014-005061-72 Phase 3, randomized, open label, controlled multi center study to evaluate the safety and immunogenicity of 4 doses of MenACWY conjugate vaccine, administered concomitantly with routine vaccines, amon... bad-data
Trial is outside EEC, and reported results 2014-005083-15 A Phase 3, Randomized, Observer-blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Novartis rMenB+OMV NZ Vaccine in Healthy Subjects Aged 11 to 17 years in Korea. bad-data
Trial is outside EEC, and reported results 2014-005105-20 A phase IV, uncontrolled, open-label, multi-center study in children and adolescents: Evaluation of long-term immunogenicity in subjects boosted with a new pediatric TBE vaccine (free of protein-deriv... bad-data
Trial is outside EEC, and reported results 2014-005106-38 A Pivotal Randomized, Single-Blind, Dose-Finding Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and Non-Adjuvanted Egg-Derived, Inactivated Novel ... bad-data
Trial is outside EEC, and reported results 2014-005107-24 Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1) 2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months bad-data
Trial is outside EEC, and reported results 2014-005128-91 Evaluating the safeness of Agrippal® S1 in preventing flu on Vietnamese volunteers. bad-data
Trial is outside EEC, and reported results 2014-005135-13 A Phase III Observer blind Single-Coordinating Center Pediatric Study in China Comparing a Booster Dose of Vaxem™ Hib to HIBERIX® When Given as Part of a Local Dosing Regimen in Infants bad-data
Trial is outside EEC, and reported results 2014-005136-33 A Phase III Observer-Blind, Randomized, Controlled, Single-Coordinating Center Pediatric Study in China Comparing Vaxem Hib to HIBERIX® Using a Local Dosing Regimen in Infants bad-data
Trial is outside EEC, and reported results 2014-005159-24 A Phase III, observer-blind, randomized, controlled, multi-center study to inventigate the immunogenicity and safety of the Vaxem Hib™ in 2-4 months old healthy infants in China, according to the reco... bad-data
Trial is outside EEC, and reported results 2014-005160-15 Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents, to Evaluate Safety, Tolerability and Immunogenicity of Four Different rMenB plus MenACWY Formulations bad-data
Trial is outside EEC, and reported results 2014-005185-30 A Randomized, Open Label, Single Center, Dose- and Regimen-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and Non-Adjuvanted Egg-Derived, ... bad-data
Trial is outside EEC, and reported results 2014-005203-24 A Post Marketing Surveillance Study to monitor the reactogenicity and safety of Vaxem™Hib when administered according to the prescribing information in Korea bad-data
Trial is outside EEC, and reported results 2014-005246-22 A phase III, observer-blind, randomized, controlled, single center study to investigate immunogenicity and safety of VaxemTM Hib in 13 - 59 months old healthy children in China, according to the recom... bad-data
Trial is outside EEC, and reported results 2014-005309-18 A Ph III, Single Arm, Multi-Center, Open-Label Study to Assess the Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent Vaccine Quinvaxem® (DTwP-Hib-HepB Vaccine) when Administered to... bad-data
Trial is outside EEC, and reported results 2015-000979-27 A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adolescent... bad-data
Trial is outside EEC, and reported results 2015-001453-32 A Phase IIIb, Controlled, Open Label, Single-Center, Persistency, Extension study in Chinese children after a 2 + 1 dose series of either CRM197- conjugate Haemophilus influenzae type b vaccine or tet... bad-data

Related organisations

Over time organisations can merge, or split.

We think Novartis Vaccines is now effectively part of GlaxoSmithKline.